Why biotech scale up strategies turn toward ASEAN

Why biotech and biopharma scale up strategies increasingly turn toward ASEAN

On the ground in Southeast Asia

Many biotech and biopharma companies eventually face the same question: Where do we scale manufacturing without increasing risk?
Once a therapy moves toward commercial readiness, the conversation changes quickly. Scientific uncertainty starts to decline, but operational pressure rises.

Phosworks is currently on the ground in Southeast Asia, working from a base in Hat Yai, Thailand. In this series we share field notes about what ASEAN clusters can realistically offer different life science companies.

In the first article we introduced a simple idea. ASEAN works best as a portfolio, not as a single destination. Different countries contribute different capabilities. The strategic question is not whether to enter ASEAN. It is how to combine the right places for the right roles. For biotech and biopharma companies moving toward commercial scale, that portfolio logic becomes especially relevant.

When science works but operations become the challenge

In biotech the hardest problems are often no longer scientific.

They are operational.

A company moves from Phase II or Phase III toward commercial readiness and the focus shifts quickly. Suddenly the key questions are about manufacturing, tech transfer, GMP readiness, reliable capacity, supply resilience and investor confidence.

At this stage many companies begin looking beyond their existing footprint. Not because their current ecosystem has failed, but because scale introduces new risks. Investors want redundancy. Supply chains need resilience. Manufacturing capacity must grow without compromising quality.

This is where ASEAN increasingly enters the conversation. In conversations with biotech teams visiting the region, the discussion rarely starts with cost. It starts with reliability.

Field note: Biotech scale up strategies rarely fail because of science. They fail when manufacturing capacity and credibility cannot grow at the same speed.

Who benefits most from an ASEAN strategy

Not every biotech company needs a regional manufacturing strategy in Southeast Asia. But certain situations appear again and again.

Mid sized biotech companies preparing for commercial production often need additional capacity without committing everything to a single site. Biopharma organizations building regional supply resilience look for complementary manufacturing nodes closer to Asian markets. Companies working with complex modalities such as biologics, peptides, conjugates, or oligonucleotides often prioritize ecosystems where capability and credibility matter as much as cost.

For these organizations the real challenge is execution.

How do you scale manufacturing while maintaining confidence from regulators, partners, and investors?

Why Singapore often becomes the credibility anchor

In many ASEAN strategies Singapore becomes the starting point. The reason is not only infrastructure but also credibility.

Singapore combines advanced research clusters such as Biopolis and one north with industrial biomanufacturing capacity in locations such as Tuas Biomedical Park. This combination sends a strong signal of capability and reliability. Investors understand the ecosystem. Regulatory expectations are clear. Talent and technology networks are well established.

Once this anchor exists, other parts of the ASEAN portfolio become easier to integrate. Companies can add complementary capabilities elsewhere in the region while maintaining a strong credibility base.

How ASEAN complements existing manufacturing networks

ASEAN rarely replaces manufacturing ecosystems in Europe or North America. Instead it extends them.

Companies often keep their most sensitive processes in established environments while adding complementary capabilities elsewhere. Additional capacity, greater operational flexibility, stronger regional supply resilience, and closer proximity to Asian markets all become possible.

When ASEAN is treated as a portfolio rather than a single location, the region becomes a strategic extension of global operations.

Where communication becomes operational

When companies begin exploring new manufacturing locations, another challenge quickly becomes visible. Understanding the strategy is one thing but trusting it is another.
Investors, partners, regulators, and internal teams all want to understand the same thing. What is being built, how it works, and why it can be trusted. Site visits and due diligence are important. But clear documentation often shapes how quickly confidence develops. Facility footage, leadership interviews, partner stories, training material, and process animation make complex operations understandable. They help organizations align around the same vision.

At Phosworks we spend much of our time working with ambitious companies that are building something new. Challenger organizations entering new markets, launching new technologies, or scaling faster than their category expects.

Those are the kinds of companies we enjoy working with. The ones creating something that deserves to be seen clearly.

Filming across ASEAN

Phosworks is currently working across Southeast Asia from our base in Hat Yai, Thailand. We help European and North American life science teams capture credible on location content across the region. Video, animation, and strategic marketing content that helps partners, regulators, and talent understand what is being built.

When companies scale into new territories, clarity builds confidence.
And confidence is what allows challenger companies to move faster than the industry expects.

Series note: This field note focused on biotech and biopharma scale up.
The next article in the series looks at another part of the ASEAN life science landscape. Medtech and diagnostics manufacturing ecosystems.